CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I/II Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02919371
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:50.420130+00:00
Published At: 2018-08-10T00:00:00+00:00
Record Updated At: 2018-08-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Renal Cell Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2018-08-10"
protocolSection.identificationModule.nctId: "NCT02919371"
protocolSection.identificationModule.officialTitle: "Phase I/II Combined Alternating Sunitinib and Bevacizumab (Avastin\u00ae) in Advanced Renal Cell Carcinoma (CASA)"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.